Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options
| Autor: | Valery Walker, Melissa D. Johnson, Elizabeth Dodds Ashley, George Papadopoulos, Manishi Prasad, Dominika Dabrowski, Barbara D. Alexander, Richard H. Drew, John R. Perfect, Robert P. Danna |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Antifungal Agents Adolescent MEDLINE Aspergillosis Severity of Illness Index Drug Costs Young Adult Pharmacoeconomics Zygomycosis Internal medicine Severity of illness North Carolina medicine Humans Candidiasis Invasive Pharmacology (medical) Hospital Costs Young adult Intensive care medicine Aged Aged 80 and over Academic Medical Centers business.industry Medical record Cryptococcosis Length of Stay Middle Aged medicine.disease Female business |
| Zdroj: | Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. |
| ISSN: | 0277-0008 |
| DOI: | 10.1002/phar.1124 |
| Popis: | Study Objective To determine the true institutional cost of treating invasive fungal infections in light of recent advances in diagnostic techniques and antifungal therapies for both treatment and prophylaxis of these infections. Design Economic analysis. Setting Academic medical center. Patients A total of 200 patients discharged from the hospital during 2004–2005 with a diagnosis of proven, probable, or possible aspergillosis, cryptococcosis, invasive candidiasis, or zygomycosis (cases). Patients were matched in a 1:1 fashion with patients having similar underlying disease states but no invasive fungal infections (controls). Measurements and Main Results Data on demographic and clinical characteristics were collected from patients' medical records. In addition, information concerning each patient's hospitalization was recorded. Resource utilization data for a patient's entire hospitalization were collected from the hospital's charge databases and converted to costs. These data were compared between the cases and the controls. After adjusting for race-ethnicity, sex, age, and comorbid illnesses, mean total hospital cost for cases was $32,196 more than for controls (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text